Dr Michael Fay

Dr Michael Fay

Conjoint Senior Lecturer

School of Medicine and Public Health

Career Summary

Biography

My research interests are in the fields of thoracic and neuro-oncology. Most of these focus on improved ways to integrate
imaging (both functional and anatomic) into clinical radiotherapy. I hold dual clinical qualifications in medical and radiation
oncology. I have a number of clinical studies presently accruing patients for which I am the local principal investigator. I am
the co-principal investigator of an international phase III neuro-oncology trial (TROG 08.02). I am also involved in a
collaboration with QIMR looking at the problems of the cancer burden in indigenous populations. I am a frequent invited
speaker at national meetings. I am an invited reviewer for the Journal of Thoracic Oncology and the Internal Medicine Journal.
I have reviewed grants for the NH&MRC. I was until recently on the advisory committee to the Queensland Cancer Physics
Collaborative.

Students and Mentoring

I am on the Queensland Statewide Training Committee of the College of Radiologists and have established the Tutorial series in Clinical Radiation Oncology. I have served on the board of the Royal Australia and New Zealand College of Radiologists and organised
fellowship exams for that college.



Qualifications

  • Bachelor of Medicine, Bachelor of Surgery, University of Otago - New Zealand

Keywords

  • Cancer care
  • Functional Imaging
  • Medical Oncology
  • Neuro-oncology
  • PET
  • Radiation Oncology
  • Thoracic Oncology

Fields of Research

Code Description Percentage
110313 Nuclear Medicine 30
111208 Radiation Therapy 40
111201 Cancer Cell Biology 30

Professional Experience

Academic appointment

Dates Title Organisation / Department
1/06/2015 -  Conjoint Senior Lecturer Faculty of Health, University of Newcastle
Australia
1/01/2015 -  Senior Lecturer The University of Queensland
Australia

Professional appointment

Dates Title Organisation / Department
1/03/2015 -  Staff Specialist, Radiation Oncology Calvary Mater Newcastle
Australia
1/06/2014 -  Honorary Senior Staff Specialist Royal Brisbane and Women's Hospital
Australia
1/06/2014 -  Radiation Oncologist Genesis Cancer Care, Lake Macquarie Private Hospital
Australia
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Chapter (2 outputs)

Year Citation Altmetrics Link
2015 Fay MF, Bell C, Dowson N, Puttick S, Rose S, 'Imaging of Brain Tumours', Molecular Considerations and Evolving Surgical Management Issues in the Treatment of Patients with a Brain Tumour, InTech, Rijeka, Croatia 235-276 (2015)
DOI 10.5772/59981
Co-authors Michael Fay
2009 Fay MF, Martin JM, Porceddu SV, O'Sullivan B, 'Acute and Late Radiation Therapy Effects', When Cancer Crosses Disciplines, World Scientific, London 179-200 (2009)
Co-authors Jarad Martin, Michael Fay

Journal article (44 outputs)

Year Citation Altmetrics Link
2016 Garvey G, Cunningham J, He VY, Janda M, Baade P, Sabesan S, et al., 'Health-related quality of life among Indigenous Australians diagnosed with cancer', QUALITY OF LIFE RESEARCH, 25 1999-2008 (2016) [C1]
DOI 10.1007/s11136-016-1233-6
Citations Scopus - 2Web of Science - 2
Co-authors Michael Fay, Jen Martin
2016 Cheng M, Fay M, Steinke K, 'Percutaneous CT-guided thermal ablation as salvage therapy for recurrent non-small cell lung cancer after external beam radiotherapy: A retrospective study', International Journal of Hyperthermia, 32 316-323 (2016) [C1]

© 2016 Taylor & Francis. Abstract: Purpose: The aim of this study was to evaluate radiofrequency ablation (RFA) and microwave ablation (MWA) as a viable salvage option for ... [more]

© 2016 Taylor & Francis. Abstract: Purpose: The aim of this study was to evaluate radiofrequency ablation (RFA) and microwave ablation (MWA) as a viable salvage option for patients with locally recurrent non-small cell lung cancer (NSCLC) after radiotherapy. Materials and methods: This retrospective study was conducted on patients who had received thermal ablation for recurrent NSCLC post-curative radiotherapy. Medical records and follow-up imaging with computed tomography (CT) and PET-CT were analysed to determine time to local progression (TTLP) and overall survival (OS). TTLP was determined according to the modified RECIST criteria. Results: Twelve patients, mean age 71 ± 7 years, received 17 thermal ablation sessions, with RFA performed for four lesions and MWA for 13. Nine tumours were squamous cell cancers (SCC) and eight were adenocarcinomas. Eleven tumours had recurred post-external beam radiation and one post-stereotactic body radiation therapy. Mean tumour size was 34.2 ± 12.8 mm, tumour stages prior to radiotherapy were Ia (2), Ib (3), IIa (4), IIb (1) and III (2). Follow-up period was 19 ± 11 months. Overall median TTLP was 14 months (95% CI: 8, 19), and median OS was 35 months (95% CI: 12, 58). Mean TTLP for tumours < 30 mm was 23 months and for tumours > 30 mm 14 months (p = 0.20). Recurrence rates reduced from 50% after initial ablation to 20% with a second ablation. Complication rate for pneumothorax requiring intervention was 17%. Conclusion: Both RFA and MWA ablation prolonged local tumour control with minimal morbidity in this study group of recurrent NSCLC after radiotherapy.

DOI 10.3109/02656736.2015.1137640
Citations Scopus - 6Web of Science - 6
Co-authors Michael Fay
2016 Fay MF, Head R, Sminia P, Dowson N, Cosgrove L, Rose SE, Martin JH, 'Valproate in Adjuvant Glioblastoma Treatment', JOURNAL OF CLINICAL ONCOLOGY, 34 3105-+ (2016)
DOI 10.1200/JCO.2016.67.2162
Citations Scopus - 3Web of Science - 2
Co-authors Michael Fay, Jen Martin
2015 Bell C, Dowson N, Fay M, Thomas P, Puttick S, Gal Y, Rose S, 'Hypoxia Imaging in Gliomas With F-18-Fluoromisonidazole PET: Toward Clinical Translation', SEMINARS IN NUCLEAR MEDICINE, 45 136-150 (2015)
DOI 10.1053/j.semnuclmed.2014.10.001
Citations Scopus - 19Web of Science - 20
Co-authors Michael Fay
2015 Bell C, Dowson N, Puttick S, Gal Y, Thomas P, Fay M, et al., 'Increasing feasibility and utility of F-18-FDOPA PET for the management of glioma', NUCLEAR MEDICINE AND BIOLOGY, 42 788-795 (2015)
DOI 10.1016/j.nucmedbio.2015.06.001
Citations Scopus - 8Web of Science - 7
Co-authors Michael Fay
2015 Puttick S, Bell C, Dowson N, Rose S, Fay M, 'PET, MRI, and simultaneous PET/MRI in the development of diagnostic and therapeutic strategies for glioma', DRUG DISCOVERY TODAY, 20 306-317 (2015)
DOI 10.1016/j.drudis.2014.10.016
Citations Scopus - 20Web of Science - 17
Co-authors Michael Fay
2015 Lindsay J, Dooley M, Martin J, Fay M, Kearney A, Khatun M, Barras M, 'The development and evaluation of an oncological palliative care deprescribing guideline: the 'OncPal deprescribing guideline'', SUPPORTIVE CARE IN CANCER, 23 71-78 (2015) [C1]
DOI 10.1007/s00520-014-2322-0
Citations Scopus - 13Web of Science - 11
Co-authors Michael Fay, Jen Martin
2015 Puttick S, Stringer BW, Day BW, Bruce ZC, Ensbey KS, Mardon K, et al., 'EphA2 as a Diagnostic Imaging Target in Glioblastoma: A Positron Emission Tomography/Magnetic Resonance Imaging Study.', Mol Imaging, 14 7290201500008 (2015)
DOI 10.2310/7290.2015.00008
Co-authors Michael Fay
2015 Fay M, Head R, Martin J, 'Where is the radiobiology and pharmacology research to improve outcomes in glioblastoma?', Journal of Neuro-Oncology, (2015) [C1]

Personalized medicine has been helpful for drug development in diseases with single and relatively stable gene mutations. The benefit for complex solid tumours with heterogeneous ... [more]

Personalized medicine has been helpful for drug development in diseases with single and relatively stable gene mutations. The benefit for complex solid tumours with heterogeneous and changing genetic profiles is less clear. Whether it is efficient to continue diverting resources from combined biological and pharmacological approaches to trial new and existing genetic ¿targeted therapies¿ for brain tumours is unknown but of developing concern in resource constrained environments.

DOI 10.1007/s11060-015-1816-z
Citations Scopus - 1Web of Science - 1
Co-authors Michael Fay, Jen Martin
2015 Rundle-Thiele D, Day B, Stringer B, Fay M, Martin J, Jeffree RL, et al., 'Using the apparent diffusion coefficient to identifying MGMT promoter methylation status early in glioblastoma: Importance of analytical method', Journal of Medical Radiation Sciences, 62 92-98 (2015) [C1]

© 2015. Introduction: Accurate knowledge of O &lt; sup &gt; 6 &lt; /sup &gt; -methylguanine methyltransferase (MGMT) gene promoter subtype in patients with glioblastoma (GBM) is ... [more]

© 2015. Introduction: Accurate knowledge of O < sup > 6 < /sup > -methylguanine methyltransferase (MGMT) gene promoter subtype in patients with glioblastoma (GBM) is important for treatment. However, this test is not always available. Pre-operative diffusion MRI (dMRI) can be used to probe tumour biology using the apparent diffusion coefficient (ADC); however, its ability to act as a surrogate to predict MGMT status has shown mixed results. We investigated whether this was due to variations in the method used to analyse ADC. Methods: We undertook a retrospective study of 32 patients with GBM who had MGMT status measured. Matching pre-operative MRI data were used to calculate the ADC within contrast enhancing regions of tumour. The relationship between ADC and MGMT was examined using two published ADC methods. Results: A strong trend between a measure of 'minimum ADC' and methylation status was seen. An elevated minimum ADC was more likely in the methylated compared to the unmethylated MGMT group (U = 56, P = 0.0561). In contrast, utilising a two-mixture model histogram approach, a significant reduction in mean measure of the 'low ADC' component within the histogram was associated with an MGMT promoter methylation subtype (P < 0.0246). Conclusion: This study shows that within the same patient cohort, the method selected to analyse ADC measures has a significant bearing on the use of that metric as a surrogate marker of MGMT status. Thus for dMRI data to be clinically useful, consistent methods of data analysis need to be established prior to establishing any relationship with genetic or epigenetic profiling.

DOI 10.1002/jmrs.103
Citations Scopus - 6Web of Science - 6
Co-authors Jen Martin, Michael Fay
2015 Hosein AN, Lim YC, Day B, Stringer B, Rose S, Head R, et al., 'The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells', Journal of Neuro-Oncology, 122 263-271 (2015) [C1]

© 2015, Springer Science+Business Media New York. Glioblastoma multiforme (GBM) has nearly uniformly fatal with a median survival of less than 2¿years. While there have not been... [more]

© 2015, Springer Science+Business Media New York. Glioblastoma multiforme (GBM) has nearly uniformly fatal with a median survival of less than 2¿years. While there have not been any novel anti-GBM therapeutics approved for many years, there has been the gradual accumulation of clinical data suggesting that the widely used anti-convulsant agent, valproic acid (VPA) may significantly prolong survival in GBM patients. This pre-clinical study aimed to determine the potential clinical utility of VPA in the treatment of GBM. Primary GBM cells were treated with VPA as a monotherapy and in combination with temozolomide and irradiation. At clinically achievable concentrations, VPA was shown to be effective as a monotherapy agent in the five primary lines tested. VPA was then used as a sensitizing agent to in vitro radiation and showed significant augmentation of in vitro irradiation therapy. In addition, when VPA, radiation and temozolomide were combined an additive, rather than synergistic effect was noted. Gene expression profiling demonstrated close clustering of triple treated cells with VPA mono-treated cells while untreated cells clustered closer with TMZ-irradiation dual treated cells. These microarray data suggest a dominant role of VPA at the gene expression level when combining these different treatment options. Moreover, in an in vivo tumor transplantation model, we were able to demonstrate an increase in animal survival when cells were pre-treated with irradiation-VPA and when triple treated. These findings provide a significant rationale for the investigation of VPA in the treatment of GBM patients.

DOI 10.1007/s11060-014-1713-x
Citations Scopus - 12Web of Science - 11
Co-authors Michael Fay, Jen Martin
2015 Puttick S, Stringer BW, Day BW, Bruce ZC, Ensbey KS, Mardon K, et al., 'EphA2 as a Diagnostic Imaging Target in Glioblastoma: A Positron Emission Tomography/Magnetic Resonance Imaging Study', MOLECULAR IMAGING, 14 385-+ (2015)
DOI 10.2310/7290.2015.00008
Citations Scopus - 5Web of Science - 5
Co-authors Michael Fay
2014 Bell C, Rose S, Puttick S, Pagnozzi A, Poole CM, Gal Y, et al., 'Dual acquisition of F-18-FMISO and F-18-FDOPA', PHYSICS IN MEDICINE AND BIOLOGY, 59 3925-3949 (2014)
DOI 10.1088/0031-9155/59/14/3925
Citations Scopus - 2Web of Science - 2
Co-authors Michael Fay
2014 Bell C, Pannek K, Fay M, Thomas P, Bourgeat P, Salvado O, et al., 'Distance informed Track-Weighted Imaging (diTWI): A framework for sensitising streamline information to neuropathology', NEUROIMAGE, 86 60-66 (2014)
DOI 10.1016/j.neuroimage.2013.07.077
Citations Scopus - 2Web of Science - 2
Co-authors Michael Fay
2014 Dowson N, Thomas P, Fay M, Jeffree RL, Gal Y, Bourgeat P, et al., 'Early prediction of treatment response in advanced gliomas with F-18-DOPA positron-emission tomography', CURRENT ONCOLOGY, 21 E172-E178 (2014)
DOI 10.3747/co.21.1772
Citations Scopus - 3Web of Science - 3
Co-authors Michael Fay
2014 Lindsay J, Dooley M, Martin J, Fay M, Kearney A, Barras M, 'Reducing potentially inappropriate medications in palliative cancer patients: evidence to support deprescribing approaches', SUPPORTIVE CARE IN CANCER, 22 1113-1119 (2014)
DOI 10.1007/s00520-013-2098-7
Citations Scopus - 13Web of Science - 12
Co-authors Jen Martin, Michael Fay
2014 Carroll JP, Protani MM, Nguyen L, Cheng ME, Fay M, Saleem M, et al., 'Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women.', Med Oncol, 31 881-881 (2014)
DOI 10.1007/s12032-014-0881-z
Citations Scopus - 8Web of Science - 7
Co-authors Jen Martin, Michael Fay
2014 Fay MF, Martin JH, Rose S, 'New imaging techniques for more effective treatment in glioblastoma', Internal Medicine Journal, 44 5-6 (2014) [C3]
DOI 10.1111/imj.12331
Citations Scopus - 2Web of Science - 2
Co-authors Michael Fay, Jen Martin
2014 Gal Y, Dowson N, Bourgeat P, Salvado O, Thomas P, Fay M, et al., 'Amorphous Regions-of-Interest Projection Method for Simplified Longitudinal Comparison of Dynamic Regions in Cancer Imaging', IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING, 61 264-272 (2014)
DOI 10.1109/TBME.2013.2282402
Citations Scopus - 1
Co-authors Michael Fay
2013 Rose S, Fay M, Thomas P, Bourgeat P, Dowson N, Salvado O, et al., 'Correlation of MRI-Derived Apparent Diffusion Coefficients in Newly Diagnosed Gliomas with [F-18]-Fluoro-L-Dopa PET: What Are We Really Measuring with Minimum ADC?', AMERICAN JOURNAL OF NEURORADIOLOGY, 34 758-764 (2013)
DOI 10.3174/ajnr.A3315
Citations Scopus - 25Web of Science - 24
Co-authors Michael Fay
2013 Goergen SK, Pool FJ, Turner TJ, Grimm JE, Appleyard MN, Crock C, et al., 'Evidence-based guideline for the written radiology report: Methods, recommendations and implementation challenges', JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 57 1-7 (2013)
DOI 10.1111/1754-9485.12014
Citations Scopus - 4Web of Science - 4
Co-authors Michael Fay
2013 Bettington CS, Tripcony L, Bryant G, Hickey B, Pratt G, Fay M, 'A retrospective analysis of survival outcomes for two different radiotherapy fractionation schedules given in the same overall time for limited stage small cell lung cancer', JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 57 105-112 (2013)
DOI 10.1111/j.1754-9485.2012.02470.x
Citations Scopus - 4Web of Science - 4
Co-authors Michael Fay
2013 Fay M, Poole CM, Pratt G, 'Recent advances in radiotherapy for thoracic tumours', JOURNAL OF THORACIC DISEASE, 5 S551-S555 (2013)
DOI 10.3978/j.issn.2072-1439.2013.08.46
Citations Scopus - 5Web of Science - 3
Co-authors Michael Fay
2012 Fay M, Thomas P, 'Functional imaging using pet and radiotherapy planning', Cancer Forum, 36 (2012)

Functional imaging with PET allows new insights into the extent of a tumour. This information has been rapidly included into treatment protocols. There are some complications in t... [more]

Functional imaging with PET allows new insights into the extent of a tumour. This information has been rapidly included into treatment protocols. There are some complications in the process, not least of which is how to define the edge of the tumour. This review outlines current uses of PET in radiotherapy treatment planning. Concepts of radiotherapy volumes are outlined and common applications explored. PET now has an established role in radiotherapy planning. It is hoped that in those areas where it has not shown benefit, the development of new PET tracers will allow further improvement. There is still much work to be done, especially in the area of standardisation of techniques.

Co-authors Michael Fay
2011 Martin JM, Brett R, Blyth J, Morrison S, Bryant D, Plank A, et al., 'Dosimetric effect of external beam planning preceding combined high-dose-rate brachytherapy of the prostate', BRACHYTHERAPY, 10 474-478 (2011) [C1]
DOI 10.1016/j.brachy.2010.10.003
Co-authors Michael Fay, Jarad Martin
2011 Bettington C, Tripcony L, Hickey B, Bryant G, Pratt G, Fay M, 'A RETROSPECTIVE ANALYSIS OF SURVIVAL OUTCOMES FOR TWO DIFFERENT RADIOTHERAPY FRACTIONATION SCHEDULES GIVEN IN THE SAME OVERALL TIME FOR LIMITED STAGE SMALL CELL LUNG CANCER', JOURNAL OF THORACIC ONCOLOGY, 6 S6-S6 (2011)
Co-authors Michael Fay
2011 Rassam LJ, Sinhal NP, Mackenzie H, Bowman RV, Fong KM, Yang IA, et al., 'THE LUNG CANCER JOURNEY - A REVIEW FROM THE PRINCE CHARLES HOSPITAL PULMONARY MALIGNANCY UNIT', JOURNAL OF THORACIC ONCOLOGY, 6 S36-S36 (2011)
Co-authors Michael Fay
2011 Martin JH, Fay MF, Udy A, Roberts J, Kirkpatrick C, Ungerer J, Lipman J, 'Pitfalls of using estimations of glomerular filtration rate in an intensive care population', Internal Medicine Journal, 41 537-543 (2011)
DOI 10.1111/j.1445-5994.2009.02160.x
Citations Scopus - 35Web of Science - 32
Co-authors Jen Martin, Michael Fay
2010 Dowson N, Bourgeat P, Rose S, Daglish M, Smith J, Fay M, et al., 'Joint factor and kinetic analysis of dynamic FDOPA PET scans of brain cancer patients.', Medical image computing and computer-assisted intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention, 13 185-192 (2010)

Kinetic analysis is an essential tool of Positron Emission Tomography image analysis. However it requires a pure tissue time activity curve (TAC) in order to calculate the system ... [more]

Kinetic analysis is an essential tool of Positron Emission Tomography image analysis. However it requires a pure tissue time activity curve (TAC) in order to calculate the system parameters. Pure tissue TACs are particularly difficult to obtain in the brain as the low resolution of PET means almost all voxels are a mixture of tissues. Factor analysis explicitly accounts for mixing but is an underdetermined problem that can give arbitrary results. A joint factor and kinetic analysis is proposed whereby factor analysis explicitly accounts for mixing of tissues. Hence, more meaningful parameters are obtained by the kinetic models, which also ensure a less ambiguous solution to the factor analysis. The method was tested using a cylindrical phantom and the 18F-DOPA data of a brain cancer patient.

Citations Scopus - 3
Co-authors Michael Fay
2010 Martin JM, Gorayski P, Zwahlen D, Fay M, Keller J, Millar J, 'IS RADIOTHERAPY A GOOD ADJUVANT STRATEGY FOR MEN WITH A HISTORY OF CRYPTORCHISM AND STAGE I SEMINOMA?', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 76 65-70 (2010) [C1]
DOI 10.1016/j.ijrobp.2009.01.027
Citations Scopus - 4Web of Science - 3
Co-authors Michael Fay, Jarad Martin
2010 Martin JH, Fay MF, Udy A, Roberts J, Kirkpatrick C, Ungerer J, Lipman J, 'Pitfalls of using estimations of glomerular filtration rate in an intensive care population', Internal Medicine Journal, (2010)
DOI 10.1111/j.1445-5994.2010.02160.x
Co-authors Michael Fay
2010 Martin JH, Fay MF, 'Surrogate end-points in clinical practice: are we providing worse care?', INTERNAL MEDICINE JOURNAL, 40 395-398 (2010)
DOI 10.1111/j.1445-5994.2010.02248.x
Citations Scopus - 6Web of Science - 6
Co-authors Michael Fay, Jen Martin
2009 de Winton E, Heriot AG, Ng M, Hicks RJ, Hogg A, Milner A, et al., 'The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer', BRITISH JOURNAL OF CANCER, 100 693-700 (2009)
DOI 10.1038/sj.bjc.6604897
Citations Scopus - 66Web of Science - 19
Co-authors Michael Fay
2009 Martin JH, Fay MF, Ungerer JP, 'eGFR - use beyond the evidence', MEDICAL JOURNAL OF AUSTRALIA, 190 197-199 (2009)
Citations Scopus - 15Web of Science - 13
Co-authors Jen Martin, Michael Fay
2009 Khamly KK, Thursfield VJ, Fay M, Desai J, Toner GC, Choong PFM, et al., 'Gender-specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthood', INTERNATIONAL JOURNAL OF CANCER, 125 426-431 (2009)
DOI 10.1002/ijc.24376
Citations Scopus - 20Web of Science - 18
Co-authors Michael Fay
2007 Fogarty GB, Cassumbhoy R, Martin JM, Fay M, Ainslie J, 'Technique for axillary radiotherapy using computer-assisted planning for high-risk skin cancer', AUSTRALASIAN RADIOLOGY, 51 267-275 (2007)
DOI 10.1111/j.1440-1673.2007.01729.x
Citations Scopus - 8Web of Science - 5
Co-authors Michael Fay, Jarad Martin
2005 Fay M, Tan A, Fisher R, Mac Manus M, Wirth A, Ball D, 'Dose-volume histogram analysis as predictor of radiation pneumonitis in primary lung cancer patients treated with radiotherapy', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 61 1355-1363 (2005)
DOI 10.1016/j.ijrobp.2004.08.025
Citations Scopus - 80Web of Science - 73
Co-authors Michael Fay
2001 Martin J, Fay MF, 'Cytochrome P450 drug interactions: are they clinically relevant?', Australian Prescriber, 24 10-12 (2001)
Co-authors Michael Fay
2001 Martin JH, Fay MF, 'Capecitabine', Current Therapeutics, 42 49-51 (2001)
Co-authors Jen Martin, Michael Fay
2001 Fay M, 'The Dana-Farber Cancer Institute', The Lancet Oncology, 2 121-121 (2001)
DOI 10.1016/S1470-2045(00)00235-7
Co-authors Michael Fay
2000 Fay M, 'Rates and risks', The Lancet Oncology, 1 62-62 (2000)
DOI 10.1016/S1470-2045(00)00119-4
Co-authors Michael Fay
2000 Fay M, 'Improving and maintaining human health', The Lancet Oncology, 1 250-250 (2000)
DOI 10.1016/S1470-2045(00)00161-3
Co-authors Michael Fay
1999 Fay MF, Nicholls MG, Richards AM, 'A man with severe, transient hypertension due to acute renal infarction', Journal of Human Hypertension, 13 343-344 (1999)
Citations Scopus - 2
Co-authors Michael Fay
Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, Phillips C, et al., 'Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.', N Engl J Med, 376 1027-1037
DOI 10.1056/NEJMoa1611977
Citations Scopus - 24Web of Science - 21
Co-authors Michael Fay
Show 41 more journal articles

Conference (15 outputs)

Year Citation Altmetrics Link
2016 Puttick S, Dowson N, Fay M, Bell C, Martin J, Rose S, 'EFFECT OF LIGAND SIZE ON UPTAKE ANDWASHOUT OF EPHA2 TARGETED THERANOSTICS FROM GLIOBLASTOMAS USING 64CU-PET', JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2016)
Co-authors Michael Fay
2016 Lehmann J, Barry M, Jones R, Fay M, 'SU-F-T-670: From the OR to the Radiobiology Lab: The Journey of a Small X-Ray Source.', Med Phys (2016)
DOI 10.1118/1.4956856
Co-authors Michael Fay
2015 Fay M, Sakoff J, Martin J, Rose S, Crozier S, Boyd A, et al., 'EPHA2 ANTIBODY INCREASES SENSITIVITY OF U87 GLIOBLASTOMA CELLS TO IRRADIATION', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
Co-authors Jen Martin, Jennette Sakoff, Michael Fay
2014 Dowson N, Thomas P, Gal Y, Fay M, Jeffree RL, Winter C, et al., 'Assessing local outcomes in heterogeneous gliomas', XVII INTERNATIONAL CONFERENCE ON THE USE OF COMPUTERS IN RADIATION THERAPY (ICCR 2013) (2014)
DOI 10.1088/1742-6596/489/1/012073
Co-authors Michael Fay
2014 Dowson N, Fay M, Thomas P, Jeffree R, McDowall R, Winter C, et al., 'Contribution of FDOPA PET to radiotherapy planning for advanced glioma', Journal of Physics: Conference Series (2014)

Despite radical treatment with surgery, radiotherapy and chemotherapy, advanced gliomas recur within months. Geographic misses in radiotherapy planning may play a role in this see... [more]

Despite radical treatment with surgery, radiotherapy and chemotherapy, advanced gliomas recur within months. Geographic misses in radiotherapy planning may play a role in this seemingly ineluctable recurrence. Planning is typically performed on post-contrast MRIs, which are known to underreport tumour volume relative to FDOPA PET scans. FDOPA PET fused with contrast enhanced MRI has demonstrated greater sensitivity and specificity than MRI alone. One sign of potential misses would be differences between gross target volumes (GTVs) defined using MRI alone and when fused with PET. This work examined whether such a discrepancy may occur. Materials and Methods: For six patients, a 75 minute PET scan using 3,4-dihydroxy-6-18F-fluoro-L-phynel-alanine (18F-FDOPA) was taken within 2 days of gadolinium enhanced MRI scans. In addition to standard radiotherapy planning by an experienced radiotherapy oncologist, a second gross target volume (GTV) was defined by an experienced nuclear medicine specialist for fused PET and MRI, while blinded to the radiotherapy plans. The volumes from standard radiotherapy planning were compared to the PET defined GTV. Results: The comparison indicated radiotherapy planning would change in several cases if FDOPA PET data was available. PET-defined contours were external to 95% prescribed dose for several patients. However, due to the radiotherapy margins, the discrepancies were relatively small in size and all received a dose of 50 Gray or more. Conclusions: Given the limited size of the discrepancies it is uncertain that geographic misses played a major role in patient outcome. Even so, the existence of discrepancies indicates that FDOPA PET could assist in better defining margins when planning radiotherapy for advanced glioma, which could be important for highly conformal radiotherapy plans. © Published under licence by IOP Publishing Ltd.

DOI 10.1088/1742-6596/489/1/012028
Co-authors Michael Fay
2014 Tam L, Meiklejohn J, Garvey G, Martin J, Adams J, Walpole E, et al., 'SUPPORTING ABORIGINAL AND TORRES STRAIT ISLANDER PEOPLE DIAGNOSED WITH CANCER TO NAVIGATE THE HEALTHCARE SYSTEM', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Co-authors Michael Fay, Jen Martin
2014 Linda N, Cheng M, Protani M, Martin J, Fay M, 'RELATIONSHIP BETWEEN OBESE WOMEN WITH BREAST CANCER, THEIR SOCIOECONOMIC STATUS AND COMORBIDITIES', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Co-authors Jen Martin, Michael Fay
2014 Cheng M, Linda N, Protani M, Carroll J, Fay M, Martin J, 'OBESITY A RISK FACTOR FOR CHEMOTHERAPY DOSE REDUCTION IN BREAST CANCER: A MULTI-CENTERED APPROACH', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Co-authors Michael Fay, Jen Martin
2014 Puttick S, Stringer BW, Day BW, Mardon K, Cowin GJ, Fay M, et al., 'EphA2 as a diagnostic imaging target in glioblastoma: A PET/MRI study', CANCER RESEARCH (2014)
DOI 10.1158/1538-7445.AM2014-LB-12
Co-authors Michael Fay
2013 Chan S-LS, Gal Y, Jeffree RL, Fay M, Thomas P, Crozier S, Yang Z, 'Automated Classification of Bone and Air Volumes for Hybrid PET-MRI Brain Imaging', 2013 INTERNATIONAL CONFERENCE ON DIGITAL IMAGE COMPUTING: TECHNIQUES & APPLICATIONS (DICTA) (2013)
Citations Scopus - 5
Co-authors Michael Fay
2012 Perry JR, O'Callaghan CJ, Ding K, Roa W, Mason WP, Cairncross JG, et al., 'A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (NCIC CTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677).', JOURNAL OF CLINICAL ONCOLOGY (2012)
Co-authors Michael Fay
2011 Fazlollahi A, Dowson N, Meriaudeau F, Rose S, Fay M, Thomas P, et al., 'Automatic brain tumour segmentation in 18F-FDOPA PET using PET/MRI fusion', Proceedings - 2011 International Conference on Digital Image Computing: Techniques and Applications, DICTA 2011 (2011)

PET-MRI fusion is widely used in oncology for early tumour diagnosis, localisation and monitoring of therapy effects. Automatic extraction of the lesions on PET images is desirabl... [more]

PET-MRI fusion is widely used in oncology for early tumour diagnosis, localisation and monitoring of therapy effects. Automatic extraction of the lesions on PET images is desirable, but remains problematic. Manual segmentation of PET images is time consuming, and restricts the definition of the tumour extent to some arbitrary threshold. This can be sub-optimal in brain tumour for instance, where tumour is diffused by nature. Moreover, when the tracer uptake is not limited to the invaded regions, it becomes more difficult for an expert to define a precise contour. In this work, we propose a soft segmentation approach to automatically segment brain tumours in 18F-FDOPA PET images using a tumour growth model. This is based on extrapolating the tumour extent starting from tumour boundaries extracted from T1W MRI. A reaction-diffusion model is utilised for the extrapolation task to obtain tumour probability density. We evaluate our method on patient's PET/MRI images. The advantage of this method is that it is completely automatic and offers a soft segmentation of tumours in PET images. © 2011 IEEE.

DOI 10.1109/DICTA.2011.61
Citations Scopus - 1
Co-authors Michael Fay
2010 Dowson N, Bourgeat P, Rose S, Daglish M, Smith J, Fay M, et al., 'Joint Factor and Kinetic Analysis of Dynamic FDOPA PET Scans of Brain Cancer Patients', MEDICAL IMAGE COMPUTING AND COMPUTER-ASSISTED INTERVENTION - MICCAI 2010, PT II, (2010)
Citations Scopus - 1Web of Science - 2
Co-authors Michael Fay
2010 Perry JR, O'Callaghan CJ, Ding K, Brandes AA, Phillips C, Menten J, et al., 'A PHASE III RANDOMIZED CONTROLLED TRIAL OF SHORT-COURSE RADIOTHERAPY WITH OR WITHOUT CONCOMITANT AND ADJUVANT TEMOZOLOMIDE IN ELDERLY PATIENTS WITH GLIOBLASTOMA MULTIFORME', NEURO-ONCOLOGY (2010)
Co-authors Michael Fay
2008 Gorayski P, Zwahlen D, Fay M, Millar J, Cattley T, Keller J, Martin JM, 'Should men with stage one testicular seminoma and a history of cryptorchism be offered adjuvant radiotherapy?', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008) [E3]
DOI 10.1016/j.ijrobp.2008.06.1149
Co-authors Jarad Martin, Michael Fay
Show 12 more conferences
Edit

Grants and Funding

Summary

Number of grants 7
Total funding $1,813,856

Click on a grant title below to expand the full details for that specific grant.


20172 grants / $52,000

EphA2 as a circulating biomarker for GBM progression - a pilot study$27,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Jennette Sakoff, Doctor Michael Fay, Doctor James Lynam
Scheme Project Grant
Role Investigator
Funding Start 2017
Funding Finish 2017
GNo G1701424
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Defining and predicting clinical toxicity in GBM patients undergoing temozolomide-radiation treatment: A multivariate study$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor James Lynam, Doctor Jennette Sakoff, Professor Jennifer Martin, Doctor Lisa Lincz, Doctor Michael Fay, Doctor Peter Galettis
Scheme Project Grant
Role Investigator
Funding Start 2017
Funding Finish 2017
GNo G1700586
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

20121 grants / $399,000

Improved diagnostic imaging of primary brain tumours$399,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team

S Rose

Scheme Project Grant
Role Investigator
Funding Start 2012
Funding Finish 2014
GNo
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON N

20112 grants / $650,731

Patterns of care, co-morbitities and quality of life in indigenous people with cancer$610,731

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team

P Valery

Scheme Project Grant
Role Investigator
Funding Start 2011
Funding Finish 2013
GNo
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON N

The development of innovative molecular imaging technology targeting improved diagnostic imaging and drug delivery for glioblastoma multiforme: A proof of concept study$40,000

Funding body: Royal Brisbane and Womens’ Hospital Annual Research Week

Funding body Royal Brisbane and Womens’ Hospital Annual Research Week
Scheme Proof of Concept
Role Lead
Funding Start 2011
Funding Finish 2011
GNo
Type Of Funding Not Known
Category UNKN
UON N

20101 grants / $637,125

Improving the Assessment of Brain Tumour Treatment Outcome using 18F-FDOPA PET - MRI Fusion$637,125

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team

S Rose

Scheme Project Grant
Role Investigator
Funding Start 2010
Funding Finish 2012
GNo
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON N

20091 grants / $75,000

Untitled$75,000

Funding body: Rotary Rockhampton North

Funding body Rotary Rockhampton North
Scheme unknown
Role Lead
Funding Start 2009
Funding Finish 2012
GNo
Type Of Funding Not Known
Category UNKN
UON N
Edit

Research Collaborations

The map is a representation of a researchers co-authorship with collaborators across the globe. The map displays the number of publications against a country, where there is at least one co-author based in that country. Data is sourced from the University of Newcastle research publication management system (NURO) and may not fully represent the authors complete body of work.

Country Count of Publications
Australia 54
Germany 6
Canada 4
Belgium 3
Italy 3
More...
Edit

News

Brain cancer clinical trial breakthrough

June 6, 2016

In a brain cancer breakthrough, an international phase III clinical trial TROG 08.02 (GBM in elderly patients), which included Australian and New Zealand researchers and patients, has found that adding temozolomide chemotherapy during short-course radiation therapy, followed by monthly maintenance doses of temozolomide, significantly improved survival of elderly patients with glioblastoma (GBM), reducing the risk of death by 33%.

Dr Michael Fay

Position

Conjoint Senior Lecturer
School of Medicine and Public Health
Faculty of Health and Medicine

Edit